Driada Semaglutide and the UK Weight-Loss Market

What the clinical evidence actually says about semaglutide for weight loss

The evidence base for semaglutide in weight management comes from the STEP trial programme, conducted in thousands of adults with obesity or overweight and at least one weight-related condition. The landmark STEP 1 trial, published in the New England Journal of Medicine, found that participants taking 2.4 mg of semaglutide weekly lost an average of around 15% of their body weight over 68 weeks, compared with roughly 2.4% on placebo — a meaningful difference in both clinical and everyday terms.

That evidence underpins the MHRA's authorisation of Wegovy, not Driada's product or any other unlicensed preparation. The licensed medicine has been through scrutiny of its manufacturing process, purity, sterility, and the precise semaglutide content per dose. An unlicensed brand has not. That distinction matters before you put anything near a syringe.

NICE has also assessed semaglutide's cost-effectiveness for the NHS, recommending it under specific criteria within specialist weight management services. That recommendation applies to Wegovy only. You can read the NICE semaglutide appraisal (TA875) if you want to understand the clinical standard the medicine was held to.

Where Driada semaglutide sits within UK law

UK law classifies semaglutide as a prescription-only medicine. The Human Medicines Regulations 2012 make it illegal to supply a POM without a valid prescription issued after a clinical assessment. Driada Medical is a brand used predominantly in research-chemical markets and is not registered with the MHRA as a medicine manufacturer or marketing authorisation holder for weight management. That means any Driada semaglutide product sold for human use in the UK is outside the licensed supply chain.

The practical consequences are real. The MHRA has warned publicly about unlicensed and counterfeit weight-loss injectables, there have been large seizures of fake pens, some found to contain insulin rather than the stated compound, with several hospitalisations reported. You can check whether any online pharmacy you are considering is properly registered using the GPhC pharmacy register, it takes under a minute and gives you an immediate answer.

A seller offering semaglutide without requiring a valid prescription is operating outside the law. That is not a regulatory technicality; it is the signal that no clinical check has happened and that the product's provenance is unknown. If you want a clear picture of how semaglutide works and what it involves, that context is worth reviewing before making any decisions.

Who the licensed treatment is actually for, and how to access it properly

Wegovy is licensed for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. Eligibility is never determined by a number alone; a prescriber weighs your medical history, current medicines, and other factors before deciding whether treatment is appropriate.

If you are looking at the doses used in weight loss treatment, it is worth understanding that the schedule runs from a low starting dose upward in steps, titrated by your prescriber over several months, and our guide to the semaglutide 1 mg dose stage explains what to expect at that point in the titration. Rushing that process, or bypassing it entirely through an unverified source, removes the safety checks built into that approach.

For people who would rather not inject, the MHRA approved an oral semaglutide tablet for weight management in June 2026 (the first of its kind licensed in the UK) giving another legitimate route worth exploring. Any of these options requires a clinical assessment first.

If you want to understand the full cost picture before starting, a look at what private Wegovy treatment involves sets out what a legitimate prescription service includes. At the end of the process, if treatment is clinically suitable for you, it is a prescriber who says so, not a checkout page.

If you are ready to talk to a clinician, check your eligibility with our prescribers and start a free consultation today.